NRIX
HEALTHCARENurix Therapeutics Inc
$16.88+0.28 (+1.69%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NRIX Today?
No stock-specific AI insight has been generated for NRIX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.20$22.50
$16.88
Fundamentals
Market Cap$1.7B
P/E Ratio—
EPS$-3.17
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume977K
Avg Volume (10D)—
Shares Outstanding103.4M
NRIX News
22 articles- Nurix Therapeutics stock (US67079U1007): Biotech firm trading with deep losses and cash cushionAD HOC NEWS·May 8, 2026
- A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000Motley Fool·May 6, 2026
- Nurix Therapeutics Inc. (NRIX): Leadership in Targeted Protein Degradation Attracts Smart MoneyYahoo Finance·Apr 27, 2026
- Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026Yahoo Finance·Apr 22, 2026
- Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsightGlobeNewswire Inc.·Apr 21, 2026
- Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29Yahoo Finance·Apr 20, 2026
- Did Sanofi Revenue Expiry and Rising R&D Spend Just Recast Nurix Therapeutics' (NRIX) Investment Narrative?Yahoo Finance·Apr 11, 2026
- Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?Yahoo Finance·Apr 10, 2026
- Company News for Apr 9, 2026Yahoo Finance·Apr 9, 2026
- Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·Apr 8, 2026
- Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewswire Inc.·Apr 8, 2026
- Nurix Therapeutics to Participate in Upcoming Investor ConferenceYahoo Finance·Apr 7, 2026
- A Look At Nurix Therapeutics (NRIX) Valuation After Strong 1 Year Return And High Price To Sales RatioYahoo Finance·Apr 4, 2026
- Alpha Cognition Inc. (ACOG) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 26, 2026
- Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?Yahoo Finance·Mar 26, 2026
- Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 25, 2026
- Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual MeetingYahoo Finance·Mar 23, 2026
- Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 19, 2026
- Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales MultipleYahoo Finance·Feb 28, 2026
- Nurix Therapeutics Stock Sees RS Rating Jump To 82Yahoo Finance·Feb 26, 2026
- Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 MillionMotley Fool·Feb 22, 2026
- Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%Motley Fool·Feb 22, 2026
All 22 articles loaded
Price Data
Open$16.60
Previous Close$16.60
Day High$16.97
Day Low$16.36
52 Week High$22.50
52 Week Low$8.20
52-Week Range
$8.20$22.50
$16.88
Fundamentals
Market Cap$1.7B
P/E Ratio—
EPS$-3.17
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume977K
Avg Volume (10D)—
Shares Outstanding103.4M
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—